




# Diagnostic value of structural and diffusion imaging measures in schizophrenia

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters

Citation	Lee, Jungsun, Myong-Wuk Chon, Harin Kim, Yogesh Rathi, Sylvain Bouix, Martha E. Shenton, and Marek Kubicki. 2018. "Diagnostic value of structural and diffusion imaging measures in schizophrenia." <i>NeuroImage : Clinical</i> 18 (1): 467-474. doi:10.1016/j.nicl.2018.02.007. <a href="http://dx.doi.org/10.1016/j.nicl.2018.02.007">http://dx.doi.org/10.1016/j.nicl.2018.02.007</a> .
Published Version	<a href="https://doi.org/10.1016/j.nicl.2018.02.007">doi:10.1016/j.nicl.2018.02.007</a>
Citable link	<a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:37298276">http://nrs.harvard.edu/urn-3:HUL.InstRepos:37298276</a>
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a>



## Diagnostic value of structural and diffusion imaging measures in schizophrenia

Jungsun Lee<sup>a,b</sup>, Myong-Wuk Chon<sup>a</sup>, Harin Kim<sup>c</sup>, Yogesh Rathi<sup>b</sup>, Sylvain Bouix<sup>b</sup>,  
Martha E. Shenton<sup>b,d,e</sup>, Marek Kubicki<sup>b,e,\*</sup>

<sup>a</sup> Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>b</sup> Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

<sup>c</sup> Department of psychiatry, Korean Armed Forces Capital Hospital, Bundang-gu, Republic of Korea

<sup>d</sup> VA Boston Healthcare System, Brockton Division, Brockton, MA, USA

<sup>e</sup> Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

### ARTICLE INFO

#### Keywords:

Classification  
Diffusion MRI  
Random forest  
Support vector machine  
Schizophrenia

### ABSTRACT

**Objectives:** Many studies have attempted to discriminate patients with schizophrenia from healthy controls by machine learning using structural or functional MRI. We included both structural and diffusion MRI (dMRI) and performed random forest (RF) and support vector machine (SVM) in this study.

**Methods:** We evaluated the performance of classifying schizophrenia using RF method and SVM with 504 features (volume and/or fractional anisotropy and trace) from 184 brain regions. We enrolled 47 patients and 23 age- and sex-matched healthy controls and resampled our data into a balanced dataset using a Synthetic Minority Oversampling Technique method. We randomly permuted the classification of all participants as a patient or healthy control 100 times and ran the RF and SVM with leave one out cross validation for each permutation. We then compared the sensitivity and specificity of the original dataset and the permuted dataset.

**Results:** Classification using RF with 504 features showed a significantly higher rate of performance compared to classification by chance: sensitivity (87.6% vs. 47.0%) and specificity (95.9 vs. 48.4%) performed by RF, sensitivity (89.5% vs. 48.0%) and specificity (94.5% vs. 47.1%) performed by SVM.

**Conclusions:** Machine learning using RF and SVM with both volume and diffusion measures can discriminate patients with schizophrenia with a high degree of performance. Further replications are required.

### 1. Introduction

Patients diagnosed with schizophrenia demonstrate a wide variety of clinical symptoms including hallucinations, delusions, formal thought disorder, and cognitive dysfunctions (Sadock and Sadock, 2007; Weinberger and Harrison, 2011). Currently, diagnosing schizophrenia or evaluating the severity of the illness is determined based on clinical symptoms and an interview, without using objective biomarkers (American Psychiatric Association, 2013). Biomarker refers to objective indications of medical state observed from outside the patient, which can be measured accurately and reproducibly (Strimbu and Tavel, 2010). Also, it can be used to diagnose the disease or to predict the severity of the illness. Establishing diagnosis without using objective information may sometimes lead to misdiagnosis, which is affected by some factors such as the race and sex of the patients, and even the experience of the clinician (Green et al., 2012; Neighbors et al., 1989).

In addition, psychotic symptoms cannot be easily determined based on an interview with the patients (Fanous et al., 2012). More objective biomarkers would be beneficial to help psychiatrists to diagnose and evaluate the illness. Many studies have tried to identify core pathological structural or functional changes in patients diagnosed with schizophrenia in order to establish biomarkers of the disease (Kubicki et al., 2007; Shenton et al., 2001).

While thousands of imaging studies have reported various structural as well as functional abnormalities in schizophrenia, these cannot be used as biomarkers at this time for several reasons: 1) some abnormalities are only present in some patients (Shenton et al., 2001), 2) there is not a clear separation between patients and healthy controls because the range of values in all measures, when compared separately, are both wide and overlapping, and, 3) patients in each study show very heterogeneous clinical characteristics.

According to several theories, schizophrenia should be considered a

\* Corresponding author at: Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, 1249 Boylston street, Boston, MA, USA, 02215.

E-mail address: [kubicki@bwh.harvard.edu](mailto:kubicki@bwh.harvard.edu) (M. Kubicki).

<https://doi.org/10.1016/j.nicl.2018.02.007>

Received 6 July 2017; Received in revised form 3 February 2018; Accepted 5 February 2018

Available online 12 February 2018

2213-1582/ © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

brain disease where subtle changes in various brain locations coexist (van Erp et al., 2016). Traditional univariate methods, which focus on gross differences in one structure at a group level, cannot detect widely distributed or subtle changes in the brain (Orru et al., 2012). Because multiple measures have been introduced and reported to be abnormal in subsets of patients, and each explains only a small percentage of the variance, a multivariate approach should be considered for diagnosing schizophrenia using MRI. Furthermore, given the enormous number of values extracted from MRI images, machine learning approaches are needed to discriminate patients from healthy controls. Several such methods can be used to create classification models by means of pattern recognition of input data, i.e., linear discriminant analysis (LDA), support vector machine (SVM), and random forest (RF).

Some studies have previously been carried out to examine psychiatric diseases using T1, PET (positron emission tomography), or dMRI with SVM, LDA, or RF (Orru et al., 2012; Bansal et al., 2012). The performance rate for predicting schizophrenia using imaging data varies, however, depending on the statistical method and the population of patients used. For example, studies using structural MRI report a performance rate that ranges from 54 to 91% (Castellani et al., 2012; Davatzikos et al., 2005; Greenstein et al., 2012; Karageorgiou et al., 2011; Kasperek et al., 2011; Kawasaki et al., 2007; Mandl et al., 2013; Mourao-Miranda et al., 2012; Nieuwenhuis et al., 2012; Schnack et al., 2014; Sun et al., 2009; Takayanagi et al., 2011; Zanetti et al., 2013). Moreover, a recent meta-analysis revealed that, when compared to structural MRI, resting state functional MRI (fMRI) shows higher sensitivity (84% vs. 76%) and lower specificity (77% vs. 79%) (Kambeitz et al., 2015). Fewer studies using dMRI alone, or in conjunction with structural MRI, have been performed than have studies using structural or functional MRI (Arbabshirani et al., 2017).

Of note, Ardekani et al. (2011) reported a high rate of performance (96% sensitivity and 92% specificity for Fractional Anisotropy (FA) images, 96% sensitivity and 100% specificity for Mean Diffusivity (MD) images) when LDA was used. Using FA (Caan et al., 2006), reported a classification error of 25% in a cohort of 34 patients with schizophrenia and 24 controls, estimated using five-fold cross validation. On the other hand (Caprihan et al., 2008), achieved a classification error of 20% using a leave-one-out cross validation approach in a sample of 45 patients and 45 healthy volunteers. Other studies have reported a 70–91% performance rate including sensitivity and/or specificity (Ingalhalikar et al., 2010; Pettersson-Yeo et al., 2013; Rathi et al., 2010). While some studies with a small sample size have shown very high performance rates ( $\geq 95\%$  sensitivity) (Ardekani et al., 2011; Fekete et al., 2013; Tang et al., 2012), a recent meta-analysis and review article reported the overall rate of accuracy for the classification of schizophrenia using imaging data ranges between 80.3% and 82% (Kambeitz et al., 2015; Arbabshirani et al., 2017).

Until now, most studies that have tried to predict schizophrenia have been performed with LDA or SVM using structural or functional MRI. In addition, studies with dMRI have mainly used diffusion measures in WM as features for classification. However, RF has shown a remarkable classifying ability regarding Alzheimer's disease with MRI data (Lebedev et al., 2014), possibly due to the following merits; 1) RF can estimate feature importance during training with little additional processes, providing better insight into the biological sense in the classification model; 2) RF is an ensemble of several decision trees and each tree is grown using a random subset of training sets and a random subset of features, which provides potential higher performance for the generalizations compared to decision tree; and, finally, 3) since RF produces non-linear decision boundaries due to the usage of decision tree, RF can outperform linear methods in capturing diverse patterns of structural or functional features that are distributed across the whole brain (Breiman, 2001; Venkataraman et al., 2010; Venkataraman et al., 2012). Despite of these merits of RF, its classification performance is not always better than other machine learning methods. It depends on the sample size, machine learning method, and features used in

classification (Khondoker et al., 2016; Salvador et al., 2017; Katuwal et al., 2015).

DMRI is a method that is very sensitive to microstructural abnormalities (Beaulieu, 2002; Kanaan et al., 2005) including demyelination, axonal loss, edema, and inflammation (Assaf and Pasternak, 2008). Therefore, dMRI can detect subtle structural GM changes in intrinsic connections (Barbas and Pandya, 1989; Tardif and Clarke, 2001). In addition, some studies have reported that decreases in membranes, axon terminals, dendrites, and dendritic spines are among the causes of the reduced GM volume seen in schizophrenia (Bennett, 2011; Costa et al., 2001; Glantz and Lewis, 2000). In fact, some studies have reported abnormalities in the GM using dMRI (Lee et al., 2016; Lee et al., 2009; Moriya et al., 2010),

There are few studies using diffusion measures on GM as a feature for classification method. In this study, we evaluated the rate of performance for the classification of schizophrenia using the RF method and SVM method, with volume and dMRI measures in GM and WM as features, and we identified which structures were important for discriminating patients with schizophrenia from healthy controls.

## 2. Materials and methods

### 2.1. Participants and clinical variables

Subjects were enrolled from the Asan Medical Center, a university-affiliated hospital. Patients who were right-handed and were between the ages of 20 and 40 years old were eligible to participate in this study. Any patients with diseases that affect brain function were excluded. In addition, patients were excluded if they were unable to complete neuropsychological testing or MRI scanning sessions. Subjects within the patient group had a diagnosis of schizophrenia, which was determined by a psychiatrist according to the Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria. Moreover, they also displayed psychotic symptoms such as delusions or hallucinations for  $< 5$  years. In addition, subjects in the control group did not have any Axis I psychiatric diagnosis themselves or any first-degree relatives with an Axis I psychiatric diagnosis.

We enrolled 91 subjects in the study, but 11 cases were excluded due to poor image quality or incidental brain lesions. Ten patients were additionally excluded because their diagnoses changed to other psychotic disorders, such as bipolar disorder, when they were re-evaluated 1–6 months after the initial enrollment. The final dataset, consisting of 70 subjects (patients:  $N = 47$ ; controls:  $N = 23$ ), was used for the analysis.

Written informed consent was obtained from all subjects. Ethical approval for the study was obtained from the local Institutional Review Board, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

### 2.2. Assessment of symptoms and neurocognition

Assessment of symptoms, neurocognition, and social cognition was completed within one week of the date of the MRI examination. All subjects were evaluated using an age- and sex-adjusted short form of the Wechsler Adult Intelligence Scale-Third edition (WAIS-III), which consisted of 6 subtests including digit span, vocabulary, arithmetic, picture arrangement, block design, and digit symbol. The psychiatric symptoms of patients were evaluated by a psychiatrist using the Positive and Negative Syndrome Scale (PANSS).

### 2.3. MRI protocol and image processing

MRI scans were performed using an 8 channel SENSE head coil on a 3 Tesla scanner (Philips Achieva). DMRI images were acquired with an echo planar imaging (EPI) dMRI sequence. One baseline ( $b = 0$ ) image and 32 diffusion gradient directions with  $b = 1000 \text{ s/mm}^2$  were also

acquired. The scan parameters were as follows: field of view (FOV):  $224 * 224 * 135$  mm, voxel size:  $2 * 2 * 3$  mm<sup>3</sup>, echo time (TE): 70 ms, flip angle: 90°, repetition time (TR): 5422 ms. Structural T1 MRI images with turbo field echo were acquired and the scan parameters were as follows: FOV:  $240 * 240 * 170$ , voxel size  $1 * 1 * 1$  mm<sup>3</sup>, TE: 4.6 ms, TR: 9 ms, flip angle: 8°.

DMRI images were upsampled to  $1 * 1 * 1$  mm<sup>3</sup> voxel size using Slicer V. 4.4 (Fedorov et al., 2012). Subsequently, diffusion tensor imaging (DTI) images were calculated with weighted least squares with an added procedure to correct tensors with negative eigenvalues from dMRI. To exclude the meninges or cerebral spinal fluid (CSF), we eroded the boundary voxels of each DTI image. Using Slicer V. 4.4 and an in-house program, we estimated FA and Trace (TR, equal to  $3 * MD$ ) images from DTI images.

T1 images were parcellated into discrete anatomical regions using the Desikan-Killiany atlas of FreeSurfer V. 5.3 (Fischl et al., 2002). This was followed by non-linear registration of T1 images with a  $b = 0$  baseline images of dMRI by Advanced Neuroimaging Tools (Avants et al., 2010; Avants et al., 2011). The same registration transformation was then applied to FreeSurfer parcellated labels. We then extracted the volume and/or mean diffusion measures (FA and TR) of 184 ROIs and used these values as features for classification. The volume of each ROI was corrected using individual total cranial volume. We have described all 504 features in Supplementary Table 1.

#### 2.4. Resampling, classification with random forest and support vector machine

Since our dataset was unbalanced, with the patient group about twice as large as that of the healthy control group, and classification with RF and SVM results may be biased by an unbalanced distribution of the sample, we resampled our data into a balanced dataset (46 patients and 46 controls) using the Synthetic Minority Oversampling Technique (SMOTE) (Chawla et al., 2002). The SMOTE is one of the most popular methods for addressing the issue of unbalance and the general idea is to artificially generate cases of the minority class using K-nearest neighbors algorithm of these cases. In addition, to make a more balanced dataset, the majority class cases are also under-sampled (Chawla et al., 2002).

Because there might be a chance of correlation among the features, we performed maximum relevance minimum redundancy (mRMR, feature selection method proposed by Peng et al., (2005)) method to select the number of important features for classification from all features ( $N = 504$ ). Then we gradually increased the number of features ( $N = 1, 2, 3, \dots, 9, 10, 11, 31, 51, \dots, 491, 504$ ) from the total number of features. After that, we performed learning and classification using these selected features and investigated the performance of later classification. (Fig. 1a).

In addition, to test the statistical significance of the classification using RF and SVM, we randomly permuted the classification of all participants as a patient or healthy control 100 times and ran the RF and SVM with leave-one-out cross-validation (LOOCV, special case of k-cross validation when k is 92) for each permutation. (Fig. 1b) We then compared the sensitivity, and specificity of the original data set and the permuted data set.

The parameters of RF used during the learning phase were as follows: number of trees (5000), number of features randomly selected at each node (square root of the number of features, 22 in our study), and size of the node (Sadock and Sadock, 2007). Size of the node in random forest is the minimal number of observations allowed in the terminal nodes of each tree, which indirectly limits the tree size in the RF method. The test sets were predicted to be a patient or a control using the model from the learning phase of the RF. By comparing the real classification of participants (patient or healthy control) with the classification predicted by the RF and SVM, we calculated measures of performance such as sensitivity and specificity using the following

formulas: sensitivity = (number of true positives)/(number of true positives + false negatives), specificity = (number of true negatives)/(number of true negatives + false positives). Since the RF generates the Out of Bag (OOB) error, we calculated the OOB error estimate.

#### 2.5. Comparisons of volume, FA, and TR in important predictors between groups

As described above, we sorted the importance of features using mRMR method. We summarized the list of 20 important features and compared their values between schizophrenia patients and healthy controls to verify that these features make biological sense.

#### 2.6. Statistical analysis

All statistical analyses were performed using R (ver. 3.4.1) (R Core Team, 2017), DMwR (ver. 0.4.1) for the SMOTE method (Torgo, 2010), random forest packages (ver. 4.6–12) (Liaw and Wiener, 2002), and e1071 for SVM (ver. 1.6–8) (e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien. R package version 1.6–8, 2017).

### 3. Results

#### 3.1. Summary of demographic and clinical characteristics

We enrolled 70 participants (23 healthy controls and 47 patients) in this study. There was no significant difference between groups for males (controls: 34.8%, patients: 38.3%,  $\chi^2 = 0.082$ ,  $p = 0.775$ ) and for age (controls:  $29.70 \pm 5.15$ , patients:  $28.68 \pm 6.23$ ,  $t = 0.676$ ,  $p = 0.501$ ). Patients had a decreased adjusted IQ score compared to healthy controls (controls:  $120.39 \pm 9.32$ ; patients:  $97.91 \pm 15.84$ ;  $t = 7.44$ ,  $p < 0.0001$ , Welch's *t*-test). The total PANSS score in patients was  $61.11 \pm 14.92$  (positive syndrome score:  $15.91 \pm 6.51$ ; negative syndrome score:  $16.77 \pm 7.08$ ; general score:  $28.43 \pm 6.82$ ). The olanzapine equivalent dose of atypical antipsychotics at the time of the MRI scan was  $15.52 \pm 8.60$  mg/day ( $N = 45$ ), and the olanzapine equivalent dose of typical antipsychotics at the time of the MRI scan was  $19.33 \pm 26.58$  mg/day ( $N = 3$ ). The duration of illness in the patients was  $1.02 \pm 1.58$  years (Table 1).

#### 3.2. Classification results of RF and SVM by the number of used features

Generally, RF and SVM showed the highest sensitivity and specificity when used approximately 71 selected features (Fig. 2).

#### 3.3. Permutation results


When the performance rate of the classification of the original group and the randomly permuted group were compared, the performance rate for the original group was significantly higher than the randomly permuted group (Table 2 and Fig. 3).

#### 3.4. Comparison values for significant predictors between the two groups

mRMR method showed the level of importance of all predictors in order to discriminate patients with schizophrenia from healthy controls. The values of the top 20 most important ROIs were compared using the Wilcoxon rank sum test between the two groups (Table 3).

### 4. Discussion

This study shows that patients with schizophrenia can be classified with high sensitivity and specificity by two different machine learning methods (RF and SVM) when 504 features from volume, FA, and TR of the brain structure are used, including GM, WM, and subcortical



**Fig. 1.** a. Flow chart of classifications of RF and SVM using selected features by mRMR method  
 Abbreviations: RF (Random forest), SVM (Support vector machine), mRMR (maximum relevance minimum redundancy)  
 b. Flow chart of comparisons of classification performances of RF and SVM between original class and randomly permuted class  
 Abbreviations: RF (Random forest), SVM (Support vector machine).

structures. Our study showed a high rate of performance (sensitivity: 87.6%, 89.5%; specificity: 95.9%, 94.5%; RF, SVM respectively), which is higher than the results found by meta-analysis (Kambeitz et al., 2015). Most studies of recent onset schizophrenia or first-episode psychosis (FEP) reported 66–91.5% performance (sensitivity or specificity)

(Karageorgiou et al., 2011; Kasperek et al., 2011; Mourao-Miranda et al., 2012; Sun et al., 2009; Takayanagi et al., 2011; Zanetti et al., 2013; Pettersson-Yeo et al., 2013; Rathi et al., 2010), which is lower than that with chronic schizophrenia (Kambeitz et al., 2015). Taking these previous studies into account, our results have more important

**Table 1**  
Demographic and clinical information.

	Healthy control	Schizophrenia	Healthy control vs. Schizophrenia
Number of subjects	23	47	
Number of Males (%)	8 (34.8%)	18(38.3%)	$\chi^2 = 0.082, p = 0.775$
Age (years)	29.70 ± 5.15	28.68 ± 6.23	$t = 0.676, p = 0.501$
IQ	120.39 ± 9.32	97.91 ± 15.84	$t = 7.44, p < 0.0001^a$
Duration of illness (years)		1.02 ± 1.58	
<b>PANSS</b>			
Total score		61.11 ± 14.92	
Positive score		15.91 ± 6.51	
Negative score		16.77 ± 7.08	
General score		28.43 ± 6.82	
<b>Olanzapine equivalent dose of antipsychotics at time of MRI scan (mg/day)</b>			
Atypical antipsychotics (N = 45)		15.52 ± 8.60	
Typical antipsychotics (N = 3)		19.33 ± 26.58	


<sup>a</sup> Analyzed by Welch's t-test.

implications. However, we should state that the application of our results to a general population of patients with schizophrenia should be carried out with caution since our small sample could not include all heterogeneous cases. Nonetheless studies that previously reported high performance (above 95% sensitivity) had even smaller sample sizes (Ardekani et al., 2011; Fekete et al., 2013; Tang et al., 2012) although a recent review paper has raised a concern about the issue of generalizability of studies with small sample size reported high performance (Arbabshirani et al., 2017). Larger study samples may include heterogeneous MRI information from both patients and healthy controls. Therefore, this increased heterogeneity can decrease the performance of the classification model.

Large training data sets, on the other hand, usually increase the performance of the classification system, and classification based on a small sample size is more unstable (Nieuwenhuis et al., 2012; Arbabshirani et al., 2017; Franke et al., 2010). We performed 100 repetitions of LOOCV to investigate the possibility of unstable results occurring due to a small sample size. One hundred repetitions of LOOCV also showed a very small range in the 95% confidence interval of sensitivity and specificity (RF: 86.8–88.4%, 95.3–96.4%, respectively; SVM:88.7–90.3%, 93.8–95.2%, respectively). This means that RF and SVM produced very stable classification. Of note, overfitting is one of important issues in machine-learning especially when trying to estimate parameters during the learning phase with small sample size and relatively large numbers of features as in our study (Arbabshirani et al., 2017). We could not find significant drop of overall performance rate when we repeatedly performed random forest with different numbers of features during the learning phase. We can assume that overfitting may therefore not significantly affect findings in our study.

We also tried to classify the cases using only MRI information. However, using MRI data alone may not be sufficient to classify cases in the early stages of the disease. Pina-Camacho et al. compared the rate of performance for predicting early onset FEP to develop into schizophrenia spectrum disorders (SSD) using different combinations of baseline clinical, neuropsychological, MRI, and biochemical information. Neuroimaging and biochemical information at baseline did not provide additional predictive value to the classification of developing SSD from FEP (Pina-Camacho et al., 2015). Besides early stages of disease, several studies have reported a more accurate rate of classifying schizophrenia when a combination of MRI and other information were used, such as genetic information (Greenstein et al., 2012) and neuropsychological results (Karageorgiou et al., 2011).

Several limitations should be noted in our study. First, classification may be carried out based on features of MRI that are related to brain



**Fig. 2.** Performance of classification (upper: sensitivity, lower: specificity) based on the number of used features  
Abbreviations: RF (Random forest), SVM (Support vector machine).

**Table 2**  
Comparisons of the performance rate of the classification of the original group and the randomly permuted group.

	Random forest (%, Mean ± SD (95% CI))		Support vector machine (%, Mean ± SD (95% CI))	
	Original class	Random class	Original class	Random class
Sensitivity	87.6 ± 4.2 (86.8–88.4)	47.0 ± 8.3 (45.3–48.6)	89.5 ± 3.9 (88.7–90.3)	48.0 ± 9.4 (46.1–49.9)
Specificity	95.9 ± 2.8 (95.3–96.4)	48.4 ± 8.2 (46.8–50.1)	94.5 ± 3.4 (93.8–95.2)	47.1 ± 9.7 (45.2–49.0)
OOB error	8.5 ± 2.8 (7.9–9.0)	52.1 ± 6.9 (50.7–53.5)		

Abbreviations: OOB (Out-of-Bag), SD (standard deviation), CI (confidence interval).

abnormalities, such as those that can be indexed by IQ, and are not specific to schizophrenia. Previous studies have reported that patients with schizophrenia have a lower IQ compared to healthy controls (David et al., 1997) and IQ levels correlate with FA and MD (Fryer et al., 2008). Patients in our study also had a significantly lower IQ than healthy controls. Therefore, RF and SVM may be able to discriminate the cases with low IQ from the cases with high IQ, rather than discriminating subjects with schizophrenia from healthy controls. While it is not easy to control the effect of IQ on MRI, we regressed out IQ from all 504 features (volume, FA, and TR values). Then we ran 100 times LOOCV using RF with 504 features. Mean sensitivity and specificity was 82.8% and 92.7% respectively, which was slightly lower than those results (87.6% and 94.5%) of RF without adjustment of IQ. In addition to IQ, although there was no significant difference of age and gender between patients and healthy controls, these factors may be leading to overoptimistic estimates. The second limitation is that the structural differences that were used during the learning and classification phase may not be core pathological features of schizophrenia. Instead, these may be structural differences induced by several factors such as medications or life style (Dazzan et al., 2005; Jorgensen et al., 2015; Lieberman et al., 2005; Vita et al., 2015). Therefore, classification was carried out based on MRI differences that may not be related to core pathological changes. The last limitation is that, as previously mentioned, the sample size in our study was relatively small. The results in this study showed high prediction accuracy, while there was a chance that several confounding factors such as age, sex, medication or IQ might be leading to overoptimistic estimates. In addition, overfitting might happen during RF procedures due to relatively homogenous samples. Although we analyzed our sample data by cross-validation and permutation to overcome the problems, there is still a high risk of overfitting. It should be considered that even though the results showed

high classification performance, their generalizability is limited. Our study used both volume and diffusion MRI data and performed RF method to discriminate patients with schizophrenia from healthy controls. The results of this study should be considered preliminary and require further replications.

**5. Conclusion**

We were able to accurately discriminate the patients with recent onset schizophrenia from healthy controls using volume, FA, and TR of GM and WM with an RF and SVM methods. In order to generalize our results further, more studies are needed with larger sample sizes that include patients with heterogeneous symptoms.


Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nicl.2018.02.007>.

**Funding sources**

This study was supported by the National Research Foundation of Korea (NRF-2012R1A1A1006514 and NRF-2017R1D1A1B03032707 to JL), Veterans Affairs Merit Award (I01 CX000176-06 to MES), National Institute of Mental Health (U01MH109977 to MES, SB, MK and YR, R01MH097979 to YR, R01MH102377 to MK and K24MH110807 to MK) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD090641 to SB).

**Conflict of interest**

All authors declare that they have no conflict of financial interest.



**Fig. 3.** Comparison of the distribution of performance between the original group and the randomly permuted group. The black lines indicate the mean and standard deviation of performance.

Abbreviations: OOB (Out-of-Bag).

**Table 3**  
Comparison of the values of the most important ROIs (N = 22) which most significantly contributed to the classification.

No <sup>b</sup>	GM/ WM/ Sub	Value	Side	Location	Mean ± SD (*10–3)		Rank sum	p
					controls	patients		
1	GM	TR	Rt	Middle temporal	2.6 ± 0.09	2.8 ± 0.12	249	0.0003
2	Sub	TR	Lt	Ventral DC	3.0 ± 0.1	2.9 ± 0.1	817	0.0006
3	GM	Vol <sup>a</sup>	Lt	Parsopercularis	5.0 ± 0.5	4.6 ± 0.5	774	0.0036
4	WM	Vol <sup>a</sup>	Rt	Inferior temporal	6.4 ± 0.7	6.1 ± 0.4	730	0.0181
5	Sub	Vol <sup>a</sup>	Rt	Inf. Lat. Ventricle	0.3 ± 0.1	0.5 ± 0.2	319	0.0057
6	Sub	Vol <sup>a</sup>	Lt	Hippocampus	4.2 ± 0.4	3.9 ± 0.4	799	0.0013
7	WM	FA	Lt	Transverse temporal	327.6 ± 36.8	353.0 ± 41.3	349	0.0169
8	Sub	Vol <sup>a</sup>	Both	4th Ventricle	1.4 ± 0.4	1.8 ± 0.5	332	0.0093
9	WM	FA	Lt	Precuneus	396.6 ± 17.0	383.6 ± 22.2	709	0.0357
10	WM	Vol <sup>a</sup>	Lt	Lingual	6.1 ± 0.7	5.6 ± 0.7	784	0.0024
11	GM	TR	Lt	Caudal anterior cingulate	2.7 ± 0.2	2.8 ± 0.2	291	0.0018
12	GM	TR	Rt	Inf. Temporal	2.5 ± 0.1	2.6 ± 0.1	280	0.0011
13	WM	Vol <sup>a</sup>	Lt	Inferior parietal	11.2 ± 1.1	10.4 ± 1.0	748	0.0096
14	Sub	Vol <sup>a</sup>	Both	CC Anterior and middle	0.6 ± 0.2	0.5 ± 0.1	666	0.1180
15	GM	Vol <sup>a</sup>	Rt	Parsopercularis	4.3 ± 0.6	3.9 ± 0.5	758	0.0067
16	GM	TR	Rt	Caudal anterior cingulate	2.5 ± 0.1	2.6 ± 0.1	341.5	0.0131
17	GM	FA	Rt	Middle temporal	152.8 ± 7.2	146.4 ± 10.0	762	0.0057
18	WM	Vol <sup>a</sup>	Lt	Frontal pole	0.2 ± 0.05	0.2 ± 0.04	735	0.0153
19	Sub	Vol <sup>a</sup>	Both	3rd Ventricle	0.8 ± 0.2	1.1 ± 0.4	290	0.0018
20	WM	FA	Lt	Precentral	393.7 ± 16.8	410.0 ± 25.8	350	0.0175

Analyzed by Wilcoxon rank sum test.

Abbreviations: GM, Gray matter; Sub, Subcortical structure; Whole, Whole brain; WM, White matter; FA, Fraction anisotropy; TR, Trace; Vol, Volume; Rt, Right; Lt, Left; Inf, Inferior; Lat, Lateral; Vent, Ventricle; Ventral DC, Ventral Diencephalon; CC, corpus callosum.

<sup>a</sup> Corrected by estimated total intra-cranial volume.

<sup>b</sup> No., order of importance of features to discriminate the patients from the healthy controls.

**Acknowledgement**

None.

**References**

American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. American Psychiatric Association, Arlington, VA.

Arbabshirani, M.R., Plis, S., Sui, J., Calhoun, V.D., 2017. Single subject prediction of brain disorders in neuroimaging: promises and pitfalls. *NeuroImage* 145 (Pt B), 137–165 (Jan 15).

Ardekani, B.A., Tabesh, A., Sevy, S., Robinson, D.G., Bilder, R.M., Szeszko, P.R., 2011. Diffusion tensor imaging reliably differentiates patients with schizophrenia from healthy volunteers. *Hum. Brain Mapp.* 32 (1), 1–9 (Jan).

Assaf, Y., Pasternak, O., 2008. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. *J. Mol. Neurosci.* 34 (1), 51–61.

Avants, B.B., Yushkevich, P., Pluta, J., Minkoff, D., Korczykowski, M., Detre, J., Gee, J.C., 2010. The optimal template effect in hippocampus studies of diseased populations. *NeuroImage* 49 (3), 2457–2466 (Feb 01).

Avants, B.B., Tustison, N.J., Song, G., Cook, P.A., Klein, A., Gee, J.C., 2011. A reproducible evaluation of ANTs similarity metric performance in brain image registration. *NeuroImage* 54 (3), 2033–2044 (Feb 01).

Bansal, R., Staib, L.H., Laine, A.F., Hao, X., Xu, D., Liu, J., Weissman, M., Peterson, B.S., 2012. Anatomical brain images alone can accurately diagnose chronic neuropsychiatric illnesses. *PLoS One* 7 (12), e50698.

Barbas, H., Pandya, D.N., 1989. Architecture and intrinsic connections of the prefrontal cortex in the rhesus monkey. *J. Comp. Neurol.* 286 (3), 353–375 (Aug 15).

Beaulieu, C., 2002. The basis of anisotropic water diffusion in the nervous system - a technical review. *NMR Biomed.* 15 (7–8), 435–455 (Nov–Dec).

Bennett, M.R., 2011. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. *Prog. Neurobiol.* 95 (3), 275–300 (Nov).

Breiman, L., 2001. Random forests. *Mach. Learn.* 45 (1), 5–32.

Caan, M.W., Vermeer, K.A., van Vliet, L.J., Majoie, C.B., Peters, B.D., den Heeten, G.J., Vos, F.M., 2006. Shaving diffusion tensor images in discriminant analysis: a study into schizophrenia. *Med. Image Anal.* 10 (6), 841–849 (Dec).

Caprihan, A., Pearlson, G.D., Calhoun, V.D., 2008. Application of principal component analysis to distinguish patients with schizophrenia from healthy controls based on fractional anisotropy measurements. *NeuroImage* 42 (2), 675–682 (Aug 15).

Castellani, U., Rossato, E., Murino, V., et al., 2012. Classification of schizophrenia using feature-based morphometry. *J. Neural Transm.* 119 (3), 395–404 (Mar).

Chawla, N.V., Bowyer, K.W., Hall, L.O., Kegelmeyer, W.P., 2002. SMOTE: synthetic minority oversampling technique. *J. Artif. Intell. Res.* 16, 321–357.

Costa, E., Davis, J., Grayson, D.R., Guidotti, A., Pappas, G.D., Pesold, C., 2001. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. *Neurobiol. Dis.* 8 (5), 723–742 (Oct).

Davatzikos, C., Shen, D., Gur, R.C., et al., 2005. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. *Arch. Gen.*

*Psychiatry* 62 (11), 1218–1227 (Nov).

David, A.S., Malmberg, A., Brandt, L., Allebeck, P., Lewis, G., 1997. IQ and risk for schizophrenia: a population-based cohort study. *Psychol. Med.* 27 (6), 1311–1323 (Nov).

Dazzan, P., Morgan, K.D., Orr, K., et al., 2005. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. *Neuropsychopharmacology* 30 (4), 765–774 (Apr).

e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien. R Package Version 1.6–8. <https://cran.r-project.org/package=e1071> [computer program]. Version; 2017.

Fanous, A.H., Amdur, R.L., O'Neill, F.A., Walsh, D., Kendler, K.S., 2012. Concordance between chart review and structured interview assessments of schizophrenic symptoms. *Compr. Psychiatry* 53 (3), 275–279 (Apr).

Fedorov, A., Beichel, R., Kalpathy-Cramer, J., et al., 2012. 3D slicer as an image computing platform for the quantitative imaging network. *Magn. Reson. Imaging* 30 (9), 1323–1341 (Nov).

Fekete, T., Wilf, M., Rubin, D., Edelman, S., Malach, R., Mujica-Parodi, L.R., 2013. Combining classification with fMRI-derived complex network measures for potential neurodiagnostics. *PLoS One* 8 (5), e62867.

Fischl, B., Salat, D.H., Busa, E., et al., 2002. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* 33 (3), 341–355 (Jan 31).

Franke, K., Ziegler, G., Kloppel, S., Gaser, C., 2010. Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. *NeuroImage* 50 (3), 883–892 (Apr 15).

Fryer, S.L., Frank, L.R., Spadoni, A.D., Theilmann, R.J., Nagel, B.J., Schweinsburg, A.D., Tapert, S.F., 2008. Microstructural integrity of the corpus callosum linked with neuropsychological performance in adolescents. *Brain Cogn.* 67 (2), 225–233 (Jul).

Glantz, L.A., Lewis, D.A., 2000. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. *Arch. Gen. Psychiatry* 57 (1), 65–73 (Jan).

Green, J.G., Gruber, M.J., Kessler, R.C., Lin, J.Y., McLaughlin, K.A., Sampson, N.A., Zaslavsky, A.M., Alegria, M., 2012. Diagnostic validity across racial and ethnic groups in the assessment of adolescent DSM-IV disorders. *Int. J. Methods Psychiatr. Res.* 21 (4), 311–320 (Dec).

Greenstein, D., Malley, J.D., Weisinger, B., Clasen, L., Gogtay, N., 2012. Using multivariate machine learning methods and structural MRI to classify childhood onset schizophrenia and healthy controls. *Front. Psychol.* 3, 53.

Ingalhalikar, M., Kanterakis, S., Gur, R., Roberts, T.P., Verma, R., 2010. DTI based diagnostic prediction of a disease via pattern classification. *Med. Image Comput. Comput. Assist. Interv.* 13 (Pt 1), 558–565.

Jorgensen, K.N., Skjaerve, I., Mørch-Johnsen, L., Haukvik, U.K., Lange, E.H., Melle, I., Andreassen, O.A., Agartz, I., 2015. Cigarette smoking is associated with thinner cingulate and insular cortices in patients with severe mental illness. *J. Psychiatry Neurosci.* 40 (4), 241–249 (Jul).

Kambeitz, J., Kambeitz-Ilanckovic, L., Leucht, S., Wood, S., Davatzikos, C., Malchow, B., Falkai, P., Koutsouleris, N., 2015. Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. *Neuropsychopharmacology* 40 (7), 1742–1751 (Jun).

Kanaan, R.A., Kim, J.S., Kaufmann, W.E., Pearlson, G.D., Barker, G.J., McGuire, P.K.,

2005. Diffusion tensor imaging in schizophrenia. *Biol. Psychiatry* 58 (12), 921–929 (Dec 15).
- Karageorgiou, E., Schulz, S.C., Gollub, R.L., et al., 2011. Neuropsychological testing and structural magnetic resonance imaging as diagnostic biomarkers early in the course of schizophrenia and related psychoses. *Neuroinformatics* 9 (4), 321–333 (Dec).
- Kasperek, T., Thomaz, C.E., Sato, J.R., et al., 2011. Maximum-uncertainty linear discrimination analysis of first-episode schizophrenia subjects. *Psychiatry Res.* 191 (3), 174–181 (Mar 31).
- Katuwal, G.J., Cahill, N.D., Baum, S.A., Michael, A.M., 2015. The predictive power of structural MRI in autism diagnosis. *Conf. Proc. IEEE Eng. Med. Biol. Soc.* 2015, 4270–4273 (Aug).
- Kawasaki, Y., Suzuki, M., Kherif, F., et al., 2007. Multivariate voxel-based morphometry successfully differentiates schizophrenia patients from healthy controls. *NeuroImage* 34 (1), 235–242 (Jan 01).
- Khondoker, M., Dobson, R., Skirrow, C., Simmons, A., Stahl, D., 2016. A comparison of machine learning methods for classification using simulation with multiple real data examples from mental health studies. *Stat. Methods Med. Res.* 25 (5), 1804–1823 (Oct).
- Kubicki, M., McCarley, R., Westin, C.F., Park, H.J., Maier, S., Kikinis, R., Jolesz, F.A., Shenton, M.E., 2007. A review of diffusion tensor imaging studies in schizophrenia. *J. Psychiatr. Res.* 41 (1–2), 15–30 (Jan–Feb).
- Lebedev, A.V., Westman, E., Van Westen, G.J., et al., 2014. Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. *Neuroimage Clin.* 6, 115–125.
- Lee, K., Yoshida, T., Kubicki, M., et al., 2009. Increased diffusivity in superior temporal gyrus in patients with schizophrenia: a diffusion tensor imaging study. *Schizophr. Res.* 108 (1–3), 33–40 (Mar).
- Lee, J.S., Kim, C.Y., Joo, Y.H., Newell, D., Bouix, S., Shenton, M.E., Kubicki, M., 2016. Increased diffusivity in gray matter in recent onset schizophrenia is associated with clinical symptoms and social cognition. *Schizophr. Res.* 176 (2–3), 144–150 (Oct).
- Liaw, A., Wiener, M., 2002. Classification and regression by randomforest. *R News* (2/3), 18–22.
- Lieberman, J.A., Stroup, T.S., McEvoy, J.P., et al., 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N. Engl. J. Med.* 353 (12), 1209–1223 (Sep 22).
- Mandl, R.C., Brouwer, R.M., Cahn, W., Kahn, R.S., Hulshoff Pol, H.E., 2013. Family-wise automatic classification in schizophrenia. *Schizophr. Res.* 149 (1–3), 108–111 (Sep).
- Moriya, J., Kakeda, S., Abe, O., et al., 2010. Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia. *Schizophr. Res.* 116 (2–3), 196–203 (Feb).
- Mourao-Miranda, J., Reinders, A.A., Rocha-Rego, V., et al., 2012. Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study. *Psychol. Med.* 42 (5), 1037–1047 (May).
- Neighbors, H.W., Jackson, J.S., Campbell, L., Williams, D., 1989. The influence of racial factors on psychiatric diagnosis: a review and suggestions for research. *Community Ment. Health J.* 25 (4), 301–311 (Winter).
- Nieuwenhuis, M., van Haren, N.E., Hulshoff Pol, H.E., Cahn, W., Kahn, R.S., Schnack, H.G., 2012. Classification of schizophrenia patients and healthy controls from structural MRI scans in two large independent samples. *NeuroImage* 61 (3), 606–612 (Jul 02).
- Orru, G., Pettersson-Yeo, W., Marquand, A.F., Sartori, G., Mechelli, A., 2012. Using support vector machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. *Neurosci. Biobehav. Rev.* 36 (4), 1140–1152 (Apr).
- Peng, H., Long, F., Ding, C., 2005. Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. *IEEE Trans. Pattern Anal. Mach. Intell.* 27 (8), 1226–1238 (Aug).
- Pettersson-Yeo, W., Benetti, S., Marquand, A.F., et al., 2013. Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level. *Psychol. Med.* 43 (12), 2547–2562 (Dec).
- Pina-Camacho, L., Garcia-Prieto, J., Parellada, M., et al., 2015. Predictors of schizophrenia spectrum disorders in early-onset first episodes of psychosis: a support vector machine model. *Eur. Child Adolesc. Psychiatry* 24 (4), 427–440 (Apr).
- R Core Team, 2017. R: a Language and Environment for Statistical Computing. Vienna, R Foundation.
- Rathi, Y., Malcolm, J., Michailovich, O., Goldstein, J., Seidman, L., McCarley, R.W., Westin, C.F., Shenton, M.E., 2010. Biomarkers for identifying first-episode schizophrenia patients using diffusion weighted imaging. *Med. Image Comput. Comput. Assist. Interv.* 13 (Pt 1), 657–665.
- Sadock, B.J., Sadock, V.A., 2007. *Synopsis of Psychiatry*, 10th ed. PA: LWW, Philadelphia.
- Salvador, R., Radua, J., Canales-Rodriguez, E.J., et al., 2017. Evaluation of machine learning algorithms and structural features for optimal MRI-based diagnostic prediction in psychosis. *PLoS One* 12 (4), e0175683.
- Schnack, H.G., Nieuwenhuis, M., van Haren, N.E., Abramovic, L., Scheewe, T.W., Brouwer, R.M., Hulshoff Pol, H.E., Kahn, R.S., 2014. Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder and healthy subjects. *NeuroImage* 84, 299–306 (Jan 01).
- Shenton, M.E., Dickey, C.C., Frumin, M., McCarley, R.W., 2001. A review of MRI findings in schizophrenia. *Schizophr. Res.* 49 (1–2), 1–52 (Apr 15).
- Strimbu, K., Tavel, J.A., 2010. What are biomarkers? *Curr. Opin. HIV AIDS* 5 (6), 463–466 (Nov).
- Sun, D., van Erp, T.G., Thompson, P.M., et al., 2009. Elucidating a magnetic resonance imaging-based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. *Biol. Psychiatry* 66 (11), 1055–1060 (Dec 01).
- Takayanagi, Y., Takahashi, T., Orikabe, L., et al., 2011. Classification of first-episode schizophrenia patients and healthy subjects by automated MRI measures of regional brain volume and cortical thickness. *PLoS One* 6 (6), e21047.
- Tang, Y., Wang, L., Cao, F., Tan, L., 2012. Identify schizophrenia using resting-state functional connectivity: an exploratory research and analysis. *Biomed. Eng. Online* 11, 50 (Aug 16).
- Tardif, E., Clarke, S., 2001. Intrinsic connectivity of human auditory areas: a tracing study with DII. *Eur. J. Neurol.* 13 (5), 1045–1050 (Mar).
- Torgo, L., 2010. *Data Mining with R: Learning with Case Studies*. CRC Press, Boca Raton.
- van Erp, T.G., Hibar, D.P., Rasmussen, J.M., et al., 2016. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol. Psychiatry* 21 (4), 585 (Apr).
- Venkataraman, A., Kubicki, M., Westin, C.F., Golland, P., 2010. Robust feature selection in resting-state fMRI connectivity based on population studies. *Conf. Comput. Vis. Pattern Recognit. Workshops* 63–70.
- Venkataraman, A., Whitford, T.J., Westin, C.F., Golland, P., Kubicki, M., 2012. Whole brain resting state functional connectivity abnormalities in schizophrenia. *Schizophr. Res.* 139 (1–3), 7–12 (Aug).
- Vita, A., De Peri, L., Deste, G., Barlati, S., Sacchetti, E., 2015. The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies. *Biol. Psychiatry* 78 (6), 403–412 (Sep 15).
- Weinberger, D.R., Harrison, P., 2011. *Schizophrenia*, 3rd ed. Wiley-Blackwell, Oxford.
- Zanetti, M.V., Schaufelberger, M.S., Doshi, J., et al., 2013. Neuroanatomical pattern classification in a population-based sample of first-episode schizophrenia. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 43, 116–125 (Jun 03).